🇺🇸 MRK — Merck & Co., Inc.
Healthcare CompraPrecio actual
150,33 USD
Máx. histórico
156,92
10 días
Caída desde máximo
-4,20%
Rango 52 semanas
77,58 – 156,92
Variación hoy
-1,32%
Cierre anterior
152,34
Rango de hoy
150,09 – 152,22
Volumen hoy
4.298.143
- Nombre completo
- Merck & Co., Inc.
- Divisa
- USD
- Mercado
- NYSE
- Sector
- Healthcare
- Industria
- Drug Manufacturers - General
- Empleados
- 73.000
- PER ⓘ
- 122,22 (puede no estar actualizado)
- Dividend yield
- 2,23% (puede no estar actualizado)
- Precio objetivo analistas
- 148,73 USD (puede no estar actualizado)
- Primera cotización
- 02/01/1962
- Precio actualizado
- hace 1 día
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Fecha de pago | Importe por participación |
|---|---|
| 31/08/1981 | 0,0172 USD |
| 01/06/1981 | 0,0172 USD |
| 02/03/1981 | 0,0172 USD |
| 02/12/1980 | 0,0172 USD |
| 29/08/1980 | 0,0152 USD |
| 02/06/1980 | 0,0152 USD |
| 28/02/1980 | 0,0152 USD |
| 03/12/1979 | 0,0152 USD |
| 31/08/1979 | 0,0126 USD |
| 25/05/1979 | 0,0126 USD |
| 01/03/1979 | 0,0126 USD |
| 04/12/1978 | 0,0126 USD |
| 28/08/1978 | 0,0113 USD |
| 26/05/1978 | 0,0113 USD |
| 02/03/1978 | 0,0113 USD |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/01/1970 | 1,46 | 1,47 | 1,44 | 1,46 | +0,00% | 2,04% | 1.803.398 |
| 15/01/1970 | 1,46 | 1,48 | 1,45 | 1,46 | -0,45% | 1,81% | 1.109.203 |
| 14/01/1970 | 1,46 | 1,46 | 1,45 | 1,46 | -0,22% | 1,13% | 550.829 |
| 13/01/1970 | 1,47 | 1,47 | 1,45 | 1,47 | -0,23% | 1,58% | 1.214.842 |
| 12/01/1970 | 1,47 | 1,48 | 1,46 | 1,47 | +0,00% | 1,01% | 679.104 |
| 09/01/1970 | 1,47 | 1,49 | 1,46 | 1,47 | -0,22% | 2,02% | 1.712.851 |
| 08/01/1970 | 1,47 | 1,48 | 1,47 | 1,47 | +0,68% | 1,13% | 520.646 |
| 07/01/1970 | 1,48 | 1,49 | 1,46 | 1,46 | -0,90% | 2,02% | 935.654 |
| 06/01/1970 | 1,47 | 1,48 | 1,46 | 1,48 | +0,79% | 1,36% | 596.102 |
| 05/01/1970 | 1,47 | 1,48 | 1,46 | 1,47 | -0,56% | 1,57% | 701.741 |
| 02/01/1970 | 1,49 | 1,49 | 1,47 | 1,47 | — | 1,55% | 498.010 |